Unknown

Dataset Information

0

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.


ABSTRACT: Among 248 consecutive patients with blast phase myeloproliferative neoplasm (MPN-BP), DNA collected at the time of blast transformation was available in 75 patients (median age, 66 years; 64% men). MPN-BP followed primary myelofibrosis in 39 patients, essential thrombocythemia in 20 patients, and polycythemia vera in 16 patients. A myeloid neoplasm-relevant 33-gene panel was used for next-generation sequencing. Driver mutation distribution was JAK2 57%, CALR 20%, MPL 9%, and triple-negative 13%. Sixty-four patients (85%) harbored other mutations/variants, including 37% with ?3 mutations; most frequent were ASXL1 47%, TET2 19%, RUNX1 17%, TP53 16%, EZH2 15%, and SRSF2 13%; relative mutual exclusivity was expressed by TP53, EZH2, LNK, RUNX1, SRSF2, and NRAS/KRAS mutations. Paired chronic-blast phase sample analysis was possible in 19 patients and revealed more frequent blast phase acquisition of ASXL1, EZH2, LNK, TET2, TP53, and PTPN11 mutations/variants. In multivariable analysis, RUNX1 and PTPN11 mutations/variants were associated with shorter survival duration; respective hazard ratios (HRs) (95% confidence interval [CI]) were 2.1 (95% CI, 1.1-3.8) and 3.0 (95% CI, 1.1-6.6). An all-inclusive multivariable analysis confirmed the prognostic relevance of RUNX1 mutations (HR, 1.9; 95% CI, 1.5-5.5) and also showed additional contribution from a treatment strategy that includes transplant or induction of complete or near-complete remission (HR, 0.3; 95% CI, 0.2-0.5). The current study points to specific mutations that might bear pathogenetic relevance for leukemic transformation in MPN and also suggest an adverse survival effect of RUNX1 mutations.

SUBMITTER: Lasho TL 

PROVIDER: S-EPMC5858483 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


Among 248 consecutive patients with blast phase myeloproliferative neoplasm (MPN-BP), DNA collected at the time of blast transformation was available in 75 patients (median age, 66 years; 64% men). MPN-BP followed primary myelofibrosis in 39 patients, essential thrombocythemia in 20 patients, and polycythemia vera in 16 patients. A myeloid neoplasm-relevant 33-gene panel was used for next-generation sequencing. Driver mutation distribution was <i>JAK2</i> 57%, <i>CALR</i> 20%, <i>MPL</i> 9%, and  ...[more]

Similar Datasets

| S-EPMC7521397 | biostudies-literature
| S-EPMC4404337 | biostudies-literature
| S-EPMC8760696 | biostudies-literature
| S-EPMC6745993 | biostudies-literature
| S-EPMC6199664 | biostudies-literature
| S-EPMC4017260 | biostudies-literature
| S-EPMC7959293 | biostudies-literature
| S-EPMC9820986 | biostudies-literature
| S-EPMC6636147 | biostudies-literature
| S-EPMC6402635 | biostudies-literature